News

It's been a challenging past three years for AbbVie (NYSE: ABBV). The pharmaceutical leader lost U.S. patent exclusivity for its top-selling medicine, Humira, and encountered a significant clinical

It's been a rough year for Sarepta Therapeutics (NASDAQ: SRPT), a small-cap biotech that develops medicines for rare diseases. The company's shares are down by 88% year to date due to safety issues

First Horizon (NYSE:FHN), a regional banking group focused on retail and commercial lending in the Southeast, released its second quarter 2025 earnings on July 16, 2025. The most important news was

There are no guarantees on Wall Street, especially when it comes to dividends. The board of directors of each company decides on the dividend in private. But income investors can glean some

What makes a good dividend stock? The answer depends a bit on who's looking, of course. But there are some general themes that can be drawn out by looking at Johnson & Johnson (NYSE: JNJ) and

A stock market that keeps reaching all-time highs hardly seems like anything for investors to complain about. But if you're trying to build a growing stream of passive income, extended bull markets

It's been an awful, horrible, lousy year so far for UnitedHealth Group (NYSE: UNH). If I opened a thesaurus, I could easily find plenty of other apt descriptions for the healthcare giant's

Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies

President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its

One of the big reasons to like Pfizer (NYSE: PFE) today is its huge 7.1% dividend yield. To put that yield into context, the S&P 500 index is yielding roughly 1.3% and the average healthcare stock a

Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader

If putting your money to work on Wall Street is something you haven't started doing because it feels like a rich person's game and you're not one, I've got good news. Discount brokerages no longer

Abbott Laboratories (NYSE:ABT), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that

After briefly dipping into bear market territory just three months ago, the S&P 500 (SNPINDEX: ^GSPC) has quickly managed to recover, rising 6.6% year to date (as of this writing). But not all

Image source: The Motley Fool.

Need a quote from one of our analysts? Email [email protected]

Abbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices

Ayrshire Capital Management LLC sold its position in UnitedHealth Group Incorporated(NYSE:UNH) during the quarter ended June 30, 2025, executing trades totaling $5.98 million.

According to a recent

One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating

A few years ago, Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. The pharma giant recorded a record of $100 billion in sales back in 2022, and saw

According to a SEC filing dated July 10, Ferguson Wellman Capital Management sold 155,436 shares of UnitedHealth Group(NYSE:UNH) during the quarter ending June 30, 2025, with transactions totaling

UnitedHealth Group (NYSE: UNH) faces a series of unprecedented challenges, from leadership crises to federal investigations, leading to a significant stock decline. Is this the end of its dominance?

What's better than a great dividend? A great dividend that's growing.

Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are healthcare

Are dividend stocks only for investors nearing or in retirement? Not at all. Consider that more than half of the S&P 500's (SNPINDEX: ^GSPC) total return over the last 50 years was due to